ICU Medical, Inc. (ICUI)
NASDAQ: ICUI · Real-Time Price · USD
130.68
-1.39 (-1.05%)
At close: Jun 26, 2025, 4:00 PM
130.58
-0.10 (-0.08%)
After-hours: Jun 26, 2025, 5:52 PM EDT
ICU Medical Stock Forecast
Stock Price Forecast
The 5 analysts that cover ICU Medical stock have a consensus rating of "Strong Buy" and an average price target of $196.75, which forecasts a 50.56% increase in the stock price over the next year. The lowest target is $187 and the highest is $209.
Price Target: $196.75 (+50.56%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for ICU Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Buy | 2 | 2 | 2 | 3 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $197 → $187 | Strong Buy | Maintains | $197 → $187 | +43.10% | May 9, 2025 |
| Keybanc | Keybanc | Buy Maintains $209 → $191 | Buy | Maintains | $209 → $191 | +46.16% | Apr 21, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 8, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $200 | Hold → Strong Buy | Upgrades | $200 | +53.05% | Dec 11, 2024 |
| Keybanc | Keybanc | Buy Maintains $198 → $209 | Buy | Maintains | $198 → $209 | +59.93% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
2.25B
from 2.38B
Decreased by -5.59%
Revenue Next Year
2.23B
from 2.25B
Decreased by -0.71%
EPS This Year
6.77
from -4.83
EPS Next Year
8.34
from 6.77
Increased by 23.23%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.4B | 2.4B | 2.5B | ||
| Avg | 2.2B | 2.2B | 2.4B | ||
| Low | 2.1B | 2.1B | 2.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.1% | 7.3% | 14.1% | ||
| Avg | -5.6% | -0.7% | 5.6% | ||
| Low | -10.7% | -7.0% | -2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.07 | 8.84 | 10.45 | ||
| Avg | 6.77 | 8.34 | 9.67 | ||
| Low | 6.42 | 7.77 | 8.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 30.6% | 25.2% | ||
| Avg | - | 23.2% | 15.9% | ||
| Low | - | 14.8% | 7.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.